The Peter Attia Drive - #121 - Azra Raza, M.D.: Why we're losing the war on cancer

Episode Date: July 27, 2020

Azra Raza is a physician, scientist, author, and outspoken advocate for reconfiguring the current model of research in cancer. In this episode, Azra discusses the content of her book, The First Cell, which takes a critical look at the outdated models being used to study cancer resulting in a lack of progress in survival rates for cancer patients. Azra offers a solution which focuses on early detection and prevention, and she concludes with an optimistic outlook for the future of cancer research.   We discuss: Azra’s upbringing, interest in oncology, and the basis for writing her book [3:30]; The lack of progress in cancer treatment over the decades [18:45]; What is holding the oncology field back? [33:15]; Do the purported advances in oncology reflect the billions of dollars spent on cancer research? [40:00]; Economics of new cancer drugs—how small increases in survival come with staggering financial burdens [47:00]; How good intentions can still lead to misaligned incentives and a broken system [1:03:00]; Why 95% of new cancer drugs fail—a critical review of the cancer research model [1:11:15]; Early detection and prevention—a potential solution to the cancer problem [1:22:30]; Coping with the loss of her husband to cancer [1:46:00]; Azra’s optimistic view of the future [1:49:30]; and More. Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/azraraza Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.  

Hey everyone, welcome to the Drive Podcast. I'm your host, Peter Atia. This podcast, my website, and my weekly newsletter, I'll focus on the goal of translating the science of longevity into something accessible for everyone. Our goal is to provide the best content and health and wellness, full stop, and we've assembled a great team of analysts to make this happen. If you enjoy this podcast, we've created a membership program that brings you far more in-depth content if you want to take your knowledge of this space to the next level. At the end of this episode, I'll explain what those benefits are, or if you want to learn

more now, head over to peteratia MD dot com forward slash subscribe. Now without further delay, here's today's episode. I guess this week is Dr. Ezra Raza. Dr. Raza is a professor of medicine and the Director of the MDS Center at Columbia University in New York. She is a practicing oncologist and a cancer researcher who has been published in over 300 peer review manuscripts. She grew up in the tentative medical school in Pakistan before moving to the United States for her clinical training, which we discuss briefly. She's an expert in myelotisplastic syndrome, which is a former pre-Lukimia and acute myeloid leukemia AML. She's a recipient of a number of wards, including the 2012 Hope Award in Cancer Research, which she shared with Nobel laureate, Dr. Elizabeth Blackburn.

Dr. Raza is an outspoken advocate for completely reconfiguring the current model of research in cancer, and the purpose of this discussion is really to dive into her beautiful book, The First Cell, which really is a completely critical look at how medical research is using the wrong types of models. My words not hers, the ROI on spending is completely out of line with what anybody would consider reasonable if they were to consider it from an objective lens. And frankly, we end with what I think is a very thoughtful discussion around what the way forward looks like. Because you could easily get through this. And I always love to speak with a person a little bit before and a little bit after.

And at the end, she said, gosh, I really, I hope we didn't get too much on to a down note. And I said, no, I don't think we did. I think that there's enough sort of hype around cancer research that it's okay to lift the sheets a little bit and show this side of things. A couple things I'd say about this episode. First of all, Azra goes out of her way both in the book and if you hear her another interview to say, look, this is not someone who considers herself a writer, this is a person who considers herself both a physician and a scientist. And in many ways, sort of wrote this book because she just really needed to talk about this stuff, to which I would say one, it's very beautifully written, but two, I was blown away at the literary sprinklings that made their way into this. I mean,

and you have to remember, we're doing this by Zoom basically or a comparable platform. So we can look at each other on video and just as sure as I'm looking at another person across me, the table, I would ask for a question and she would respond by quoting Emily Dickinson. It not just quoted like I've memorized this, but quoted in the most lyrical way. So I think if you're a fan of literature, science, you have an interest in oncology, there are a lot of things you'll get out of this episode. So I'll leave it at that and I hope that you do enjoy my conversation with Dr. Ezra Raza. with Dr. Ezra Razzar. [♪ OUTRO MUSIC PLAYING [♪ [♪ OUTRO MUSIC PLAYING [♪

Ezra, thank you so much for not just making time to be here today, but as you told me before, we started setting aside a lot of time. It's an honor to sit with you. I've known a little bit about you before your book was published, because one of my colleagues knew about you and said, hey, this is an amazing woman who's in the process of writing an amazing book and you're definitely going to want to not only read it, but more importantly, I think speak with her and be able to interview

her and talk more broadly about this subject matter. And it's hard to believe that that was probably a year ago, if not more. You're an oncologist by training. And I've seen a couple of your short interviews, though I've gone out of my way to not listen to you on previous podcasts who is not color how I wanna talk with you. But the two times I've seen you

on very short clips on YouTube, you've made it very clear that you are not a writer, which I find ironic, given how well you write. So at what point did you decide that a book was an appropriate tool to communicate the amazing ideas that we're going to spend a lot of time getting into? Thank you Peter for having me on your podcast. I have been an admirer of your work and of the kind of wellness philosophy that you propose, you belong to, you practice, you propagate, you promote, I love it all. And the number of things you do is very admirable.

So it's really a pleasure to be on your podcast. I have to tell you that Dorothy Parker once said that if one of your friends come to you and they say they want to write a book, the second biggest favor you can do them is give them a copy of the elements of style by Stronken White. And of course, the first favor is killed immediately. So I knew all along that I'm never going to write a book because I'm going to, I'm a big admirer of Dorothy Parker. And then what happened Peter is that one of my dear friends in New York who happens to be a literary agent and John Brockman and his wife, Katinka, would often talk to me and say, Asra, how about writing a book? And I would say, no, I'm not a writer. And they would say,

well, you're ranging us with the same things for 10 years. All that is wrong. You want to do something, you want to change the field, write a book. I will get it published. And I would keep saying, no. Until I had, of course, as an oncologist, number one, after 30 years of being in the field, I had a little bit to say. But then the second thing is that I'm also being a basic science researcher. I've had a very active lab all along.

And my third credential is that I'm a cancer widow. So I have experienced oncology from all three perspectives. As an oncologist who sees 30 to 40 patients a week for the last 30 plus years, as a basic researcher who has had a well-funded lab for 35 years, and as someone who stood on both sides of the bed at the same time of a cancer patient, who was the love of my life. So even these credentials Peter were not sufficient to motivate me to write the book. What did it was my daughter Sheher Zad's best friend since 15 years of age, not her boyfriend, her best friend who is gay, Andrew. At 22 years of age finds the field's weakness in his arm and taken to the emergency room. He's quadriplegic within hours and he's found to have a 9 centimeter large brain tumor,

which was unresectable and pathology showed that it is one of the most malignant tumors ever known to mankind, Glowblastroma multifonial. When this boy opened his eyes and he told his diagnosis, the first thing he told his mother Peter was, mom, don't worry, just call us. She's on the cutting edge, she will cure me. So here I am, it slapped me in the face physically, that on the one hand, the ferociousness and violence of his tumor, and on the other hand, the utter helplessness of all of us, his oncologists, to do anything about it. Our complete failure in front of Andrew. How is it possible that we are so spectacularly failing

a 22-year-old boy? That's what forced me to write the book. Someone once said, and I'm sure it's been paraphrased, and so I won't attribute it, because I don't know where it came from. But the only reason to write a book is If you absolutely can't not write it and it sounds like that's sort of where you were After all of the things that you've described which is not only losing Harvey which I think he died in 2002. Is that correct?

And then the story about Andrew who obviously was about 60 70 years too young to die from anything, let alone a GBM, which is a tomb where I've certainly spoken about on this podcast before, and I think we'll talk a little bit more about it. Also, the other things we're going to talk about, which are the sort of the structural failings of the system that you felt were, if I were going to sort of try to describe your book, a big part of it is the return on investment has been very poor. That's sort of one way to summarize it. There are many ways to sort of summarize it, but an overarching theme has been, it hasn't been that we haven't spent a lot of money, it hasn't been that we haven't made some progress, it hasn't been for a lack of trying, but by any objective metric that we would apply to any standard of anything else, the return on that investment has been so paltry that

if we are not smart enough to at least consider doing something totally different, we're completely deluded. And again, I think that's one tiny piece of it. And that's probably that burning piece that I think your agent one tiny piece of it. And that's probably that burning piece that I think your agent was ultimately saying, this is either gonna erode a hole through the gastric lining of your stomach or you better put it on paper. Yes, I agree.

So let's start with oncology. What drove you to oncology? Why did you choose to become an oncologist in an era when women could have chosen far less demanding fields in medicine, not that any field in medicine is more or less demanding, but oncology is about as demanding as it gets. What was the thinking for you?

That's an astute observation, actually, because when I was going into oncology, it was the least popular field. In fact, most people when I said I'm going into oncology, it was the least popular field. In fact, most people when I said I'm going into oncology thought, okay, she couldn't get into any other fellowship. That's why. Because only Indians and Pakistanis go into oncology. Who else would in their right minds would want to go?

Except for me, it was a deliberate choice. So Peter, I was born and raised in Pakistan. But since I was a little girl, since as far back as four years old, that is my first memory, I was very interested in the natural world around me. I would be at four years, I'd be following Ants and all, and imagining all kinds of things and started reading about science for as far back as I remember really. And as I was growing up, I got more and more interested in different fields. Emberiology at one point became an obsession.

By the time I was 16, I had read all about evolution and evolutionary biology. I had become a big Darwinian fan. Everything I was looking at was through the prism of evolution for a long time, but then had I grown up in a country where choices were available to me, I'm confident that I would have gone into molecular biology as a pure science or some of the one of two study, one of the natural things like marine biology, maybe you're probably like marine biology, maybe you're probably m-mur-mucology ants. But in Pakistan where I grew up, there was no possibility of entering science except through medicine. So very cleverly, I thought I'm going to go join medical school. As soon as I complete, I will proceed to the West and there I will start my PhD in real scientific training.

But the problem that happened with me was in third year of medical school when I saw my first patient, one look was all it took. And I realized from that moment on that all of my life would be devoted to somehow use the best that science has to offer to reduce human suffering. And I have stuck to that. The second thing that happened was, so I knew that I

will do research in science, but it would be therapy driven and the patient will be front and center for me always. Second thing that happened was that I was in Karachi, Pakistan. Karachi is the largest city in the country. And people who get sick around Karachi in the suburban areas have no access really to medical care. It's a very impoverished third world country with a very overcrowded city where I grew up. So cancer patients, when they came to came Peter they would travel long distances on their donkey carts and on foot. By the time they came they would have hugely advanced tumors that I've never seen since. Even in Pakistan we don't see them now. But back then in the early 70s the kind

of end stage malignancies prouting through breasts or like huge lumps, just breaking out of people's heads and arms and sarcomas that I saw. So it was the malevolence of the tumor, the violence of the disease on the one hand, on and the other hand, the intellectual challenge of trying to figure out how this whole thing began in a single cell and how that cell goes rogue, what journeys has it undertaken to reach this level of a legacy. So it was the dual emotional as well as intellectual grip that basically caught me and at a young age. And I'm confident that if I'm given 70 more lives, I will do exactly the same thing 70 more times. Do you still remember that first patient you saw as a third year medical student? Do you remember anything about them, what condition

they had, anything about them, the way they looked. Actually, thank you for asking. Absolutely. The patient was a young woman with acute myeloid leukemia. And she was very strange because she presented with a very large spleen as well. So we knew that she must have had a prior myeloproliferative myelodisplastic, some sort of a preter cell that led up to the acute ukemia. So right there and then I started having discussions with my teachers that how much easier

it would be to study a liquid tumor because cells are already in suspension and you can go in and sample them so many times instead of trying to study a solid tumor, which is a mass that you can only remove once next time it appears, it wouldn't even be the same tumor, and you don't have the luxury of accessing the tumor before, during and after treatment. So that patient is etched on my brain as if it was yesterday's breakfast. Yeah, I find that phenomenon to be interesting amongst many physicians, both oncologists and not oncologists. Steve Rosenberg, who is my mentor, talks often about a patient that changed the course of

his life when he was early in his residency, a patient that had metastatic gastric cancer to the liver five years earlier was basically sent home to die. Shows up in the ER to have his gallbladder taken out should have been dead five years less six months earlier. He's completely free of tumor, which ultimately after double triple quadruple checking led Steve to conclude the only way this is possible. This is back in 1968. As if his immune system eradicated that cancer and Steve became one of the people who has pursued that to incredible ends. And though I've done nothing special, I still remember the first patient I saw in the hospital.

And so though it wouldn't become the catalyst for anything particularly unique, we send first year medical students on day one into clinic. They can't do anything. They are literally there to just watch and try not to get in the way. But I selected oncology and I went to the medical oncology clinic and I remember that very first patient on that very first day. And I still remember strange details like what the color was of the clothing of different people in the room that day. He had stage 4 colorectal cancer. There was probably one of the first times I'd ever seen a CT scan and certainly seen it

with such a clinical emphasis on, okay look, these are now tumors that have spread to both sides of his liver, the primary tumor was here, you can see all of these places. I would go on to become very close friends with that patient who ultimately died two years later. His widow would come to my medical school graduation two years after that. So yeah, there is something really special about medical education and it can totally derail the best laid plans of becoming the world's expert on ants. Yes, and by the way, I do teach a course that is Foundation of Clinical Medicine, where

first year medical students at Columbia University are exposed to being clinic. And I'm mindful of this experience. How is this going to change the rest of their lives? The experience has to be somehow, we can't take away the pain. It's like Emily Dickinson said, tell all the truth but tell it's learnt. Success and circuit lies. Too bright for our infirm delight, the truth superb surprise.

As lightning to the children, eased with explanation kind, the truth must dazzle gradually or every man be blind. I'm very mindful of that when first-year students come to me. As a, you're the only person who's going to not just quote Emily in the midst of discussion, but do so eloquently. And to think that there was any doubt you were a writer is only comical to me, but we'll come back to that. So when you finished medical school, not only did you realize you wanted to be a clinician, but I think the hook of oncology was already well into you. Yes, absolutely. Now let's pivot for a moment to allow you to explain to the listener

what the state of oncology looked like at that time. Specifically, when you consider what it meant to have metastatic cancer. And let's, for a moment, posit that we're going to talk about solid organ tumors separately from liquid tumors. If a woman had breast cancer, and either at presentation or later, it had spread to her lungs, to her brain, to her bones, if a man had prostate cancer that had spread to his bones, if a person had colon cancer that had spread to their liver, what was the prognosis and how long would they be expected to survive? I think to start with Peter, the important thing is that when I started in oncology, it

was almost a stigma to have cancer. The kind of causes of cancer we were taught were basically either there's a genetic or hereditary component where you have a predisposition for high risk of some sorts of cancers or is it some environmental exposure, some kind of toxins that you've been facing or pathogens. Pathogens were considered a very exciting new avenue for research at the time, that maybe it's a viral disease of some sort, especially retroviruses. And clearly, there was already a very strong component of association with things like smoking. So while there were these kinds of positive factors for cancer, most people who presented already had rather advanced diseases and very little screening measures were being performed at the time.

So they would come with, in Pakistan, especially with the kind of of text book pictures of fungating masses coming breaking through breasts and women or men suddenly showing up within with complete urinary blockage unable to to urinate and we would have to do emergency kinds of things. It was just it would be quite devastating. And of course, there were people who, women who felt a lump and came in. And so I remember how many times I was assisting and mastectomies and considered for a long time to go into surgical oncology, because that seemed to be the cleanest treatment at the time. Cut it out, you don't have to start chasing the last cancer cell with these poisonous things we were giving. Even radiation was quite primitive at the time and quite terrible

to patients. So it was all in all, it was a stigma to begin with, people didn't want to talk about it, the many people hit it, the tumors from themselves even would delude themselves into thinking that this is some kind of an infection and will go away. So most people presented with advanced cancers. The problem that I see though before I end this answer is that today in 2020, if you want to measure the success of treatment in cancer, then the thing you need to look at Peter is what is the age adjusted mortality of cancers today? In 2020, you know what it is? It is the same as it was in 1930. That's interesting. I usually make the statement. It's the same as 1970. I didn't realize it was still the same as not you go back even further.

I usually just make the point that in 50 years it hasn't changed. You're saying in 90 years it hasn't changed. Yes, I'm saying that because the 30% or 27% decline in mortality we are seeing in the last 30 years is Following a 30 years increase in mortality from in cancer. You see what happened was that with all the smoking Anyone who watches mad men is shocked to see it like my daughter saw it and she was mommy is that what people used to be like every Where they were just smoking everybody was smoking This led to such an increase in the incidence of cancer so that the decline in mortality basically parallels the decline in smoking. That is all that has happened. Otherwise, we are really at square one. And that is the embarrassment that nobody wants to recognize. In fact, somebody asked me the other day, what exactly is your point in saying, I said, look,

Nietzsche's thus-pakes are a true straw. Opens with this man running around with a lamp at noon in the middle of the market saying, I'm looking for bond. For me, it's like I'm running alone looking for an adult in the room. Yeah, so let's explain to people, let's explain some of the nuance here, because most people are confused by what an extension in disease-free survival means. Not that the average person knows what the difference is between a PR and a CR, but you and I both know this world well because we've been on the inside of how these clinical trials are run. So we understand that, hey, this drug got approved because X number of people met the criteria for a PR which has a kind of a funky arbitrary definition if you're going to be brutally honest of what a partial response is defined as a complete response is a little easier to define. But then we don't talk about what durability means in all of these things.

So I could give an entire saliliqui and lecture on this, but I'd much rather listen to you do it eloquently because the chance that you're going to quote more poetry is reasonably high. So can you explain for folks what it means to have a partial response, a complete response? And there isn't, I think it's important to do this, even though it sounds a little dry, you're saying things that seem completely at odds with what the propaganda machine is saying. Now, I know you're right because I know how the sausage is made. I've been inside the belly of the sausage. I understand how to read the literature.

That is actually asking a lot for someone who maybe just wants to better understand oncology, but they haven't had the luxury of training in oncology, or even more importantly, I think, doing research in oncology. So, can you go through some of the fundamentals of what these semantics are that are used, how these terms get thrown around, and how ultimately it can lead to some statements, like the one you just made, frankly, which is as extreme as extreme could be with respect to saying, hey, look, in 90 years, we really haven't gotten better at extending life in people with cancer once they have cancer. So let's unpack some of these definitions a bit. I think that's a good place to start.

So let me begin by a little bit of just history because before we get into nuances, why not just talk about the very gross facts? Cancer is a very bad disease. Everybody knows it. The only good news you can give to a cancer patient is that, oh, we caught it early, so we can get rid of it. So we know that cancer itself may not kill. It's the delay in treatment that really kills. So the earlier we pick it up, the better. How have we treated cancer which has been found even in mummy? So we know cancer has existed all along, but the incidents probably it is a disease of modernity associated with many many of our lifestyle changes from hunter-gatherer society to modern human. Nonetheless, cancer was identified in mummies and has been there all along in human history. How have we treated it? Well, the first treatment of cancer, even though it wasn't even called cancer, then was in 500 BC, when the Persian queen, Atosa, had felt a lump in her breast.

She tried to hide it by covering it with sheets and things and eventually asked her Greek slave who took out his sword and simply slashed off her breast. She survived it. She was the wife of Darius and she survives it. And this is the first known surgery. Weaver-slashing women's breasts in 500 BC. What is the primary treatment for breast cancer today? Same slashing. And we typically give whole-stead credit for that. So this is my point that for 2500 years, what has exactly changed? Slight and better scalables and giving anesthesia while doing it? Okay, yes. Then second is that when you couldn't, so whatever cancer was detected early enough as a solid tumor was cut out and the liquid tumors you couldn't cut out, so you needed to poison them somehow. Now, how do you poison these things? There's really nothing

could be done about it until in the first world war. Of course, it wasn't called the first world war because we didn't know there's going to be a second. So, it was called the Great War. Part of development of weapons against each other was use of chemicals. And so, when these vats of chemicals were sitting around that were dropped on humanity, people noted that one of the side effects that people died from was low blood counts. So good men and gill men, two pharmacologists sitting around in Yale decided that this

could be used to treat cancer than these chemicals. So do you know the first three chemical weapons that were used to treat cancer? Scytoxin, chlorambusil and malfilan. We still use at least two of those. I gave all three with my own hands to my own husband Harvey. So we are slashing, we are poisoning the same way, and then burning with radiation therapy the same way. So I wanted the audience to understand the kind of dramatic statements or melodramatic statements that I'm making

are not baseless. People just have to stop deluding themselves, open their eyes and see what is in front of them. So, to just finish this part with a quotation of statistics, in this day and age today, 68% of cancers that we diagnose, new cases, 68% are cured, cured with what? killed with bot-peater, slash poison burn, surgery radiation and chemo, except for a few cancers where there are targeted therapies or antibodies available, really not much has happened. The 32% who present with advanced disease that we can't use slash poison burns. So imagine the same treatments that were working in earlier stages are not working in later stages.

This is the best proof that the only thing we can do right now is to find the cancer earlier and even some of the therapies not working like targeted therapies may work better if we don't give them to stage four. Flit three mutations, got early, may respond much better to flit three inhibitors. This is the point I will keep making over and over. I want to stop you for a second there, Ezra, because honestly, that is something that I have only in the last few years come to share your zeal for, and I can't emphasize it enough. So there was a day when I believed, incorrectly now, I believe

that I was incorrect, that burden of tumor was not the primary determinant factor. Stage 4 cancer was stage 4 cancer, whether the burden was high or low, and it was really a property of the biology of the cancer that was the issue. So in other words, if you took a whole bunch of women with stage 1 breast cancer, you took a hundred women that had sub-centimeter lymph node negative breast cancer, and you had a machine that could tell you which ones had the potential to go on to have metastatic cancer versus those ones that did not. And let's maybe breast cancer wasn't a great example because of the hormone complexity of it. That whether you acted then or acted later,

it wasn't going to matter. Well, I no longer believe that is true for reasons I could expand upon. I want to emphasize the point you're making, which is, I mean, it's the contrapositive of your point, which is we don't really have therapy that works for systemic disease. So metastatic breast cancer, metastatic colon cancer, metastatic prostate cancer, metastatic, you fill in the blank, you are no better off today than you were 50 years ago. And that is a very sobering, if not outright depressing statistic. It's very difficult for the average person to comprehend that for all our advances, once colon cancer has gone to your liver in 2020. You are almost as hopeless as you were in 1970. And in fact, you can probably put more color around it and say, well, technically Peter, you might live four and a half more months.

And I don't want to discount that. I want to talk about what the cost of that is. But I mean, do you agree with, am I also being a little too dramatic or would you agree with my assessment? I think you're using myosis, meaning understated. Seriously, how do you tell a 22-year-old Andrew that we will add four months to your life? You should go and celebrate and proclaim from the rooftops. What kind of nonsense is this?

Four months of improvement in survival. And that is the lucky one who get it. You know what it is? Why people will be shocked? Why should they be shocked? They'll be shocked because they are listening poor things have been subjected to the ultra hype of all this self-promotion of scientists and oncologists patting themselves on the back for game changes that they have. Allow me to expand on what has in my opinion put the field back by decades. And that is the treatments that are most celebrated in co-cancer are treatment of chronic myeloid leukemia. cancer or treatment of chronic myeloid leukemia. This is a disease which is a disease of the myeloid cells in the bone marrow which undergoes a chronic phase where nothing much is happening except one

fine day something mutate something happens the disease takes off into an accelerated phase and then becomes acute leukemia and it is universally. And all of us who are older like me have taken care of dozens of these patients who died in our own hands, young people, as well as old. Well, it turned out that chronic myeloid leukemia is caused by one genetic change that can be targeted with one magic bullet and that magic bullet is Gleevec and that was FDA approved in 2000 and now these people are being cured with one drug and this is a fantastic success but Peter the same drug doesn't work when the disease starts to accelerate.

So chronic myeloid leukemia, think of the word chronic hair. It's not really a malignancy. It's like a pre-leukemia right now. You caught it early that at that stage there was only one problem and you could fix it with one bullet, right? Can we put that in perspective for people? Because I want to make sure we're not. I don't want the naysayer to have too much wiggle room to say, well, you've discounted the success stories. GleeVAC, we're going to probably talk about some of the checkpoint inhibitors as well, which have probably been the single biggest victory in the past five years.

Do we have a sense of what percentage cancer mortality has come down on the back of Gleevec, not just from CML, but let's also look at GI stromal tumors, which have at least for some period of time responded to Gleevec, though it might not be the most durable remission ever. I mean, what type of numbers are we talking about? Has that put a 1% dent in cancer mortality in the past 20 years? If that. It's a very rare disease. Yeah, exactly.

Very rare, but it did prove a point, which is that targeted therapy can work. This is the point I'm making that it's not even really a cancer yet, in all its malignant manifestations that other cancers are. The second thing we celebrate is again in hematologic malignancies which is acute pro-minocytic leukemia which is cured with arsenic or with vitamin A analog, vitamin A, let's say after, it cures acute pro-minocytic leukemia one of the deadliest acute leukemia. But do you know it wasn't as if scientists sat down, studied this disease, found the lesion of retinoic acid receptor and started to reverse it.

Who are Chinese were saying for years that we are curing acute promylocytic uptinia with vitamins, and the West didn't believe them. And finally they sent somebody over and they saw all the patients and were convinced and came back and did a trial of Atrahid and then were convinced and then worked backwards to find the molecular lesion. So please scientists do not take credit in front of me for a cute from myocytic leukemia. You did not work it out. you only worked it out in retrospect. So those are the two biggest advances. Now lymphomas absolutely agree that throwing cocktails of chemotherapy together, testing this one and that one they worked, as because of the biology of the disease that was responsive to those chemotherapy, that's what I'm telling you,

that some of the things that have retarded progress in a way is because we become convinced of a paradigm that, oh, if Hodgkin's disease can be cured with these four drugs, we just have to find the right four drugs for pancreatic cancer or a variant cancer, and we'll fix it. And that's how we kept working. Throwing crazy combinations of drugs together to follow the paradigms, the few successes that

we had seen, Hodgkin's disease, a few non-Hodgkin's lymphomas, or acute pro-milosotic leukemia, chronic myeloid leukemia. I mean, my multiple myeloma now has been very successfully treated, but at that time it wasn't, but now it is definitely night and day difference. But these are again rare types of cancers, melanoma, dramatic differences in survival today. But again, all of these together would account for less than 10% of cancers together. Still we have to go back to whatever we can flash poison and burn and Successfully we are able to do that for 68% cancers either because their disease is responsive like in Hodgkin's lymphoma

Even if it's advanced or non-Hodgkin'sphoma or CLL or because it is amenable to surgery, that's it. So where a counterargument here is, look, this is going to be a game of inches and the 10% that you just described, you basically gave the tour de force explanation of oncology's greatest hits in the last three decades. And again, we didn't pay a lot of, spend a lot of time on it, but I think the checkpoint inhibitors also have this huge impact beyond just melanoma because anybody who shows up with a checkpoint mutation, even if you have Lynch syndrome and you go on to get pancreatic

adenocarcinoma, you're probably going to respond. Let's just say that adds up to 8% or 9% of the 68%. So the skeptic would say, but look, Hasura, like that's amazing progress. Give us another 40 years. Give us another 30 years and cancer is eradicated. That would be the optimistic view of this. How would you counter that view? view of this, how would you counter that view? I don't want to counter anything. I mean, that's the way the field has been. I've been hearing the same self-satisfied voices, saying the same thing. How wonderful they are, how they will understand every intracellular signaling pathway in the cancer cell and reverse it. How they will understand the metabolism. Don't even get me started on that because it's as if the last 100 years haven't existed.

And people haven't had any ideas until these new investigators came around to on their white horses with their overconfidence and contempt for the past, armed with new things. We are going to reverse all these. I mean, clearly whatever advances there are, and I don't want to argue with anyone about advances. You are saying there are a lot of advances, great. Do they really reflect that quarter of a trillion dollars we have invested in research? Is this all we have to show a few checkpoint inhibitors? Fine, I agree with you. Even if I agree with you. So let's just talk about immune therapy for a minute. You say checkpoint inhibitors, there are many different kinds of immune therapies, 14, 15 different kinds.

The two most popular we talk about when we talk about immune therapy these days is either the cell therapies that are given Where you train the lab that is the pioneer of all of this work with cell and cytokine IL therapies combined with T cells etc. Or the checkpoint inhibitors because normal cells will have signals on themselves saying, eat me or don't eat me and these can be masked and these signals are the checkpoints. And by using drugs, you can unmask the signal which has been covered up by the cancer cell, very simple explanation for checkpoint. So the two main ideas in immunology that came along were how to target these checkpoints so that the body's own immune cells can recognize the cancer as being alien to the normal functioning of the body and must be eliminated.

And the second is, can you take the body's own immune cells and engineer them in such a way that they can selectively kill cancer. And CART cells have been proclaimed once again as revolutionary. Of course, the science behind it is beautiful, it's very sophisticated. It's really, it's one of those things that make you want to celebrate humanity's accomplishments. It is just a gorgeous thing. But the problem is that it has done very little

for patients. Why? Because what all the oncologists talking about Carti never mention in any of their talks. And by the way, every morning, I run every morning. And after I run, I jump on a small trampoline for 20 to 30 minutes every day, because that's one way to stimulate your lymphatic system. And the trampoline is small rebounder, I should say, not a trampoline. It's one of the best exercises you can have. I've been doing it for 25 plus years.

So during that time, I listen to YouTube lectures, to all of you, tensor researchers, out there understand that there is one person who listens to your YouTube lectures every single day. And the kinds of things people confess to in public forums, very different than the scientific papers they're writing. In all of those talks, I have never heard any serious scientist, oncologist or immunologist say that their CAR-T cells cannot distinguish between normal and cancer cells.

They just ignore that. It's like they just don't want to acknowledge it. Why don't you say that? Basically, Carti cells are just in the form of killing machine indiscriminately. So what Carti cells do is whatever antigen you put on it and whatever organ expresses that antigen, it will go destroy the whole organ, taking down every normal cell of that organ also. So basically the only thing Carti is working for right now is B cells because you can replace B cell function. After you kill every single last B cell in the body, but you can't

do that to pancreatic, can't serve because it will kill the whole pancreas. And then you can't replace the function. But how many times have you heard people say this feature? Well, I mean, do you hold out hope that some of the case studies, because we've seen the case studies, the Kalangil Karsanoma here, the pancreatic cancer there, the colon cancer, the breast cancer there, where they are able to identify the unique antigen of the cancer. And by unique, I mean distinguishing antigen of the cancer such that you can send the T cell loose and it can eradicate not the entire biliary system, but just the cancerous piece. And to be clear, I'm not speaking one way or the other, other than to sort of help me

think through the, is this a sufficient proof of principle that we believe that adaptive self-therapy of which cars are the most foreign, away the most prominent and checkpoint inhibitors are really going to be the way the future. You didn't allude to it. You and I know this as well as Tuesday follows Monday. There are also very nasty side effects of checkpoint inhibitors. And for every patient we see who has a response to them, some of the autoimmunity can be quite devastating. And in fact, Vidaligo for a patient with melanoma might not be such a fatal form of autoimmunity, but certainly when people have life-threatening and arocolitis, yes, they're cancer-free, but they die from

bowel disease that follow. So certainly not to suggest these are benign. I guess the point is, do they represent a demonstrable step-function forward that now puts us in a new era of, okay, we we found a new beast that goes beyond surgery radiation and indiscriminately killing chemicals. How do we figure out how to tame this new beast? Does that resonate? No, not particularly because Pestee Brosenberg has found this age as a goal, that this is the right way to go. But yes, we are making advances, and I do think that all of these need to continue.

I'm not saying we should stop any of this. I'm just pointing out where the field is right now. I think these are fantastic. They should continue what needs to stop. Here's the problem. 95% of experimental agents that we bring to the bedside today, 95% in cancer fail completely. The 5% that succeeds should have failed because they are only prolonging survival

for 20 to 30% of patients by a few months and you began by asking me, what is progression-free survival, what is, I mean, we don't even talk about survival anymore. We just talk about progression-free survival because survival has become too big of a obstacle to overcome. So as long as you don't see the tumor, but the patient dies within the same four months or five months, it doesn't matter, but you didn't see the tumor, but the patient dies within the same four months or five months It doesn't matter, but you didn't see the tumor for two and a half months. That's progression free survival

So this drug should be approved and the sponsors of the drug will make billions of dollars Let's stop on that because it is just so darn important. Let's use a tangible example a so darn important. Let's use a tangible example, a Vastin. Okay, I don't want to put you on the spot because I don't remember the numbers of Avastin, but the only reason I bring it up, is that okay, do you know enough of the examples that I could use Avastin?

I mean, I don't use it myself, but I do know that it's one of the more successful. We could pick another one that you know. I'll explain. So Avastin was a blockbuster in the sense that it was the first of its kind, and it explored a brand new idea. So, Judith Folkman had this idea that many others followed in the footsteps of, which is, look, if a tumor can't make new blood vessels,

it can't get very big. Therefore, the ability to make new blood vessels must be of paramount importance to metastases. And therefore, this concept of neovascularization became key. And so this was a beautiful story of science and pursuing this thesis and doing all of these experiments. And one step leads to another. And before you know it, you have a whole class of drugs called anti-vegete drugs of which this drug.

And I assume it was Genentex drug. I can't even remember at this point, but I think it was Genentex that was the first in line. They have this drug, a vastine, and I believe Colorectal Cancer was one of the first places they looked, again, in the show notes, will have the story more accurately laid out. But the gist of what I remember, asura, is the following. laid out, but the gist of what I remember as is the following. You took a patient that had metastatic colorectal cancer, which again means this is a patient who had a colon cancer that has left the colon, left the lymph nodes, it is now somewhere else usually in the liver. This is a patient who is absolutely not going to live, And if one percent of those people live five years, that would be very generous.

And this is asking the question, if you use all of the standard therapies we have today, the entire cocktail of chemotherapies, and then you do the same thing, but you also use a vastine. How much do you change the median survival? Notice we don't use mean because that can be very impacted

by outliers. We use median. And I believe the answer with Avastin was on the order of four months, with Avastin, which cost at the time in the neighborhood of $100,000, it was going to extend median survival for those patients by four months. And what I remember most about the discussion, Ezra, is it prompted a discussion about what is the value of a life? And different countries around the world, especially countries without private insurance, but instead those with public insurance

had to put something called a quality at the front of that discussion, a quality adjusted the front of that discussion, a quality-adjusted life year, which says, do we believe that the cost of a life is worth $100,000 such that a publicly funded insurance for health would be accountable to spend that money? And if you don't like that example because I might not have the details right, that you can use a thought experiment, which is if I told you, Asra, you have a condition that is going to allow you to die, but I could extend your life by a month and it's going

to cost a billion dollars. Do we as a society think that that's a reasonable cost for society to bear on your account, despite how wonderful you are and how much amazing stuff you could do with an extra month. So it started to get into this discussion of the cost benefit analysis, which gets to that return on investment. Do you wanna use a better example,

a more recent example than a vast, and to illustrate how relatively small changes in median survival or disease-free progression. And maybe you can explain the difference between those two because you and I will go back and forth between them, but I think the listener could be confused. And then again, just talk about the literal economics of that because I do think people will be staggered by what the actual numbers are. You know, John Dunn said something very beautiful.

So when you said, give a literal example, I'm going to give a literary example. No man is an island, entire of itself, each a part of a piece of the continent, part of the main. Any man's death diminishes me. That's what you said.

What is a human life worth? John Dunn says, any man's death diminishes me because I am for mankind and therefore never sent to know for whom the bell tolls. It tolls for thee. Of course, every human life is important and of course, every oncologist is working to try and save every human life. I'm not saying we are deliberately not doing enough. In fact, in all of my career in this country, in the last 43 years, I have yet to meet an oncologist who didn't care for their patients.

Never. They're all trying their hardest. But it's like trying to use a map to find your way in London, but you're using a map of Paris. It's not going to work. So how have we become so misdirected? You asked me to give a more recent example or something, I am familiar with. I started landed in this country in 1977 as a fresh medical graduate.

Before my residency could start, I had six months and I'm not someone who can sit around at home doing nothing. So I asked my sister, my older sister who had just finished a rotation. She was a pediatric resident in Buffalo, New York. I was staying with her and she just finished a rotation at Roswell Park Cancer Institute. And I said to her that you know all the oncologists there, can you get me in there and I'll just work for six months that I have. So she went and spoke to her boss, Arnie Freeman, and he said, well, if she's half as good as you, we'll take her. So I joined pediatric oncology at Roswell Park, but within a couple of months, it was very clear I couldn't handle it. I couldn't last because I was crying the whole time. I just can't handle children being sick.

So my sister's friend who happened to be my boss at the time, Judy Oaks, one day just took me by hand because I was hiding in a room crying away. I had lost a four-year-old that day and took me to the adult oncology unit where I met Harvey Priceler who was later to become my husband and Harvey was heading the leukemia program at the time at Roswell Park. And he took me on. I started working on the wards immediately. At that time, we used to have 20, 30 AML patients, acute myeloid leukemia patients on the floor.

And I started seeing and working completely as a fellow, I was hired as a fellow. We were using two drugs to treat AML back then in 1977, a combination of Aracy and Donomyce. They were popularly known as seven and three because you give seven days of one and three days of another. By the way, Harvey and I started to use this seven and three as a kind of a code word between us.

We would be sitting in a meeting and how we would suddenly leave no one and say to me, as that person is doing seven and three. And for us, that seven and three men, somebody is using seven words when three would suffice. Another mark of a great writer. So we were using seven and three, 1977. Guess what we are using in 2020, seven and three. All these years, imagine the thousands of patients I personally have had to see and describe the same side effects and the same potential benefits they will have. Now, when I started, the survival was 10% five years survival with 7 and 3.

Today with the same drug it's about 26%. Why has it increased? Because the supportive care measures are better. We have better antibiotics. We can give more platelets and red cell transfusions are easier to give. We've learned to manage better. That's it.

The supportive care is better, but the backbone of treatment is the same 7 and 3. So now a company comes up with combining these two drugs, 7 and 3 in a fatty envelope. So they come up with this new drug now and it's the same seven and three. But it gets approved in this country and this approved form which is I believe for a little older patients like 60 to 75 years if you have acute myeloid leukemia you can get this combination of seven in three which is inside this fatty capsule. Now the regular 7 and 3 costs $5,000. $5,000 for how long? For the 7 days and 3 days. For the 7 plus the 3 days for one cycle.

Okay. $5,000. This fancy version, 7 and 3 costs $45,000. And do you know what is the improvement in survival under the best conditions when they ran the study where you select patients, the eligibility criteria are so stringent, their kidneys have to be working, their liver has to be working, their lungs have to be at capacity, etc., etc. working their lungs have to be at capacity, et cetera, et cetera. You know how we choose and select patients for clinical trials. They are the best of the best. Right. They have to be cherry picked. They represent the upper limit of what you expect in the real world. Yes. And even in those cherry-ficked patients,

the basis on which this $45,000 combination is approved is an improvement in survival by 3.7 months. That is a median improvement in survival, which means a fraction of the patients, like maybe 30% experience 3.7 months improvement in survival. What does that mean? Median survival. So even out of those 30% half of them didn't even experience that.

But we are paying $45,000. Now, if I don't prescribe that drug and continue to give 7 and 3, then I can go to jail because tomorrow, if the patient dies, which they eventually do, because it's an older age group, then the family will sue me. Dr. Raza, this drug was available. It could have given 3.7 more months. So now the decisions that we are making as individuals on colleges are not being made by us. They are made just by key opinion leaders

or the very institutions like FDA, which are supposed to protect the patients. I have fallen a victim to this kind of propaganda where under the pressure of advocacy groups who are demanding more drugs for cancer patients at any cost. Just to be able to say that we have 72 new drugs being approved this year for cancer. Look at the fantastic advances we have made. So under pressure from advocacy groups from patients, the FDA has lowered its bar of approving drugs to laughable criteria. It would be laughable if it wasn't so tragic. Here you have 3.7 month median improvement in survival for a fraction of the patients for 45,000 dollars instead of 5,000. Are you surprised then that 42% of cancer patients who are diagnosed today will be completely financially ruined by the second year of their diagnosis.

50% of breast cancer women are being hounded by collection agencies with stage 4 cancer. Your friend Marty McCary has written a fabulous book, The Price.P. People should read that book and see the obscenity we have reached. The vulgarity of it all completely not thinking about patients at all, talking in terms of, well, Azra, 3.7 months mental, not to my patient who could go and attend his son's graduation or grandsons. Bar Mitzvah. Yes, of course, like I said, John Dunn said, every human life is important, but you asked the question earlier at what cost to the others? I mean, I think Marty's work does a great job of explaining this. And the only way I can sort of explain it is, I think the United States

has basically become the one that has to subsidize the rest of the world in terms of medical research. I mean, that's the only way I can sort of make sense of how outrageous these costs are. By the way, that's not a justification. So I could go on for days as to how frustrating it is, but it has basically become a form of subsidy. And I've been trying to get my head around, what are the biggest drivers of spending in the United States? Because overall, as a country, we don't get a lot in exchange for what we give. That's going to be a very polarizing comment I just made, so let me clarify it. If you take someone in the top income tax bracket

in Canada, by all estimates a socialized country, you compare them to someone in the top income tax bracket in the United States, especially in a high tax state, they're paying about the same amount. The difference, however, in what they get is fundamentally quite different in Canada. Everybody gets health insurance, no ifs, ands or buts. Everybody basically gets exceptional education at a fraction of the cost, homelessness, mental health. A lot of these issues are just so much better. I still think, I would still make the case, by the way, that the extremes of healthcare are better

in the United States. I would much rather receive my medical care in the United States than in Canada. But ultimately, it points to a gross inefficiency in terms of how those dollars that are collected are then turned around and spent. And I could probably point to three things that the United States is disproportionately spending money on that other countries are not spending money on. And it's those three things that are creating the biggest gap.

And one of them is healthcare. There's simply no way to avoid it, and within the morass of healthcare, drugs might be one of the most egregious examples. There are others that are less sexy to point your finger at, but as you note, I mean, Marty makes a very good point that the drug story is a revolting one, actually. After her we died with a five-year-long battle with leukemia. You are in your early forties at this point in time basically when you're widowed? When you died in the past years and we had a four-year-old daughter. When he was diagnosed so after he died my youngest sister who's now the head of women's radiology at the Brigham. She said, well, I have to get you out of Chicago

because this five years of thinking of nothing concentrating continuously on this one thought only, which was Harvey and his illness. So we went to England because well London is one of my favorite cities. And I wanted to take my daughter to see Reading Jail because I'm a big Oscar Wild fan. And we went to Reading and the reason I'm telling you this is one of the most gorgeous ballads ever written, the ballad of Reading Jail. The refrain is very beautiful. Yet all men kill the things they love by each let this be heard. Some do it with a bitter look and some with a flattering word. The coward does it with a kiss, the brave man with the sword, but each man kills the thing they love. Let my each let this be heard.

So while rode this poem, when he was in this ballot, when he was incarcerated in jail, and when he came out, his boyfriend, Lord Alfred Douglas asked him, what do you mean by this refrain, all men kill the things they love. What does that even mean? All men kill the things they love. And while tried to just disarm and said, well, nothing, you know, it's just whatever. But Bozy, Alfred Douglas kept insisting, no, you have to tell me what this means. So you know what? While said he said, look, it's like this. He said, look, it's like this. When we meet someone or we have an idea, we make immediately an impression in our mind. We meet them the next time and they don't correspond with the impression we had.

So instead of correcting our impression, we start trying to change the person and this is how we enter the cycle of self-dilusion and kill the thing that we love. Why am I telling you all this is because we started with good intentions, Peter. But somehow remember in the beginning I said I'm looking for an adult, Why aren't we taking stock of the situation? Why is it that scientists who are going to now, let's say, attack the metabolic pathway of cancer cells to improve the efficiency of chemotherapy by simultaneously changing the dietary patterns for the patient, a very good target to think about. But before even a phase one trial has started, they are monetizing it, making companies out of it. I mean, yes, this is a capitalist system, everything is legal, everything is allowed, but then it somehow leaves such a bad taste in my mouth all the time. All the time, it's all about, think about it.

You are never going to be able to cure an advanced cancer of the kind that Andrew had by a diet of any sort. Or even by supplementing chemotherapy, he's getting with a diet of any sort or even by supplementing chemotherapy, he's getting with a diet of any sort. All you're aiming for is improving. Their survival by a few months. But more important is to make companies. Why? Why have we come to this? I mean, I think in defense of that type of idea, which I don't really know about specifically, they would probably argue changing nutrition. If a change in nutrition could have a comparable benefit to a change to the use of a drug, it's a fraction of the cost and presumably without the destruction of the quality of life. I mean, one of the things I'd like you to come back to, as well,

is- I'm not questioning the idea at all. I'm questioning why do you have to monetize everything? Is what I'm questioning? Yeah, I mean, I was going to ask you the same question, which is, how do we think about the role of pharma in this entire landscape. I mean, it can't be denied, which is progress has to be funded by somebody.

You have different animals, so you have public funding, which has been the majority of it through NIH, via NCI, which is by far the largest of the institutes within NIH, and has done the lion's share of the cancer funding. So I actually did the analysis five years ago, which means it's probably dated, but directionally correct. But if you went back to the declaration by Richard Nixon of the war on cancer, so circa

71, 72, more than half of the total research dollars in the world into oncology funneled through NCI. Slightly over half was my recollection. Again, I could be a little wrong on that, but that's a big piece of it. Of course, Pharma, as you know, has really outsourced R&D. They just don't do R&D anymore the way they used to. So they basically now acquire R&D any more the way they used to. So they basically now acquire R&D products. And so smaller and smaller companies, which means it's shifting more to venture type investing

and biotech investing, is taking that early stage one, early stage two risk, at which point pharma brings in for the huge capital allocation required for late stage two and stage three approval that gets the drug approval, which then gets to the point you raised, which is you've got these two drugs that have been off patent for since Moses was throwing tablets at people. What are you going to do with it? Well, you could keep selling them for $5,000, or you could repurpose them and increase by nearly 10x. And I know that it sounds egregious.

I don't have an answer though, because I don't really, like this is almost to me a question of economics, is the answer that all of this stuff has to be done publicly so that shareholder value is no longer the thing that's being optimized for, because as long as these companies have to answer to shareholders, I don't think they'll ever figure out a way to put the woman with breast

cancer who's going to go bankrupt ahead of their shareholder. As awful as that sounds, I think they're always going to say I have a fiduciary responsibility to my shareholder and that is to maximize the price. And I do think the government is doing a better job at catching the most egregious examples of company that are grossly exploiting this. But in the end, is Kytrude a really worth what it's being charged today? I don't know how to answer that question. I really have no clue how to answer that question. And you've more eloquently than me said, every

life is valuable. And that includes the lives that remain, which I think is a very important point. That's the counterpoint that's never made. It's not just the life of the individual that we're debating extending by 3.1 months at some unbelievable sum. It's the lives of everybody that remains and what it says about their social security check and what it says about their schools and what it says about their healthcare. Wait, I want to answer this. If you take a live in live in frog and you throw it in boiling water, it will jump out. But if you put it in cold water and start heating it slowly, it will die in that. Because it has been

desensitized so slowly. We began all these things with good intent. That's what I keep saying to you over and over. Some of the saddest things to me are this. 95% drugs we bring to the website fail. Why? Because the pre-testing platform we are using are so artificial. We are taking a very complex disease like cancer and we are trying to reduce it by reductionist approaches into trying to replicate this complexity in mouse models, tissue culture cell lines and if those don't work, we add layers upon layers of complexity to it by generic engineering, immune compromization of the animal. You know after reading my book The First Cell, a young woman wrote to me saying, Dr. Razah, I am a PhD student. I'm working on this

cell line model of breast cancer testing drugs against it, but using a two and three dimensional in vitro system. And once this is successful, that the drugs work against the cell lines, then I will go to the mouse model. And if that works, then I have to go to human. But reading your book, I realize that it's all a waste of time. What should I do? Is this even something I should spend the next 10 years of my life doing? So, but 90% of research is still funding things. Research dollars, you are talking about NCI dollar, what are the funding for God's sake?

The same old, same old ancient platforms which have shown a 95% failure rate and the 5% success is ludicrous. Secondly, before you go, can you say more about that? Actually, I'm glad you brought this up because I sometimes forget that I know a lot of the things you're talking about and I take them for granted But I think this is worth a bit of a detour if you don't mind explain to people What that PhD student was doing what is a day in the life for her or what is she going to spend years doing and how does that sort of model fall short? I Sort of model fall short. I think you can explain it better than me because you have spent so much time in Dr. Rosenberg's lab,

but very simply stated when we want to try and find new drugs for cancer, we can't give drugs directly to humans. So we try to first give them to something in our lab. What should that something be? Well, it started by taking patients tumor cells, but they don't last very long in our cultures, in the lab. What should that something be? Well, it started by taking patients tumor cells, but they don't last very long in our cultures in the lab. So then that becomes a problem. How should we perpetuate these cells in culture? By serendipity, some cancer cells began to grow in the lab. And one of the first was the famous Hela cells from a patient with cervical cancer. And these cells grew so well that they became immortalized, they self perpetuated, they can be grown

from flask to flask, transferred from lab to lab, they can be put into mice and grow. And so all this reproducible system that became available is called a tissue culture cell line and we learned with time to make more and more of these. So you make a pancreatic cancer now just like the Hela Selver cervical cancer, you take a variant cancer, a pancreatic cancer, you grow them and one of them will by chance mutate enough to become immortalized and then become the tissue culture line. Now you can test drugs against it. But one of the first things that I have written in my book in the first chapter is that by

using these cell lines, when it was tested to see what kind of genes are they expressing, it turns out that instead of expressing genes that were faithful to the tissue of origin from which they came. For example, an ovarian cancer cell line should be expressing genes that are expressed in ovarian cancer. Pancreatic cancer cell lines should be expressing pancreatic genes. Instead it turned out that there has been a transcriptomic drift that basically all the cell lines irrespective of their tissue of origin express similar genes that make them survivable under adverse in vitro conditions.

So let me explain one other thing for the listener here, which kind of ties in another theme of yours, which is because when you go back to what we learned in the Great War, killing cancer cells is easy. I've had guests on this podcast before who have eloquently stated, there's no one sitting in a home right now that doesn't already have 30 chemicals under their sink that will kill every cancer, including the most devastating cancer like the one that killed Andrew. The challenge is killing cancer and not killing everything else. And so now, when you fast forward to what you just said, when you have immortalized in vitro cultures that have become so genetically skewed that they no longer actually represent a human cancer, you will learn a lot

about what it takes to kill them and not kill them. It just won't be relevant to the species of interest, which is a human being. This is why I read the Oscar Wilde thing to you that all men killed the things. They love. We started with a good thing when it didn't correspond to what we were hypothesizing. Instead of changing our concept, we keep tinkering. We're trying to change the other thing. This is exactly how you kill whatever you started out with. And you know what's worse, Peter? Is that 90%, 90% I want the audience to hear this clearly.

90% of the papers published in the highest profile journals of science are irreproducible. I didn't know it was that high, it's still that high. Up to 90 percent, in different studies, some show 30 percent, some 80 percent, some 90 percent, it is unconscionable what we are doing. Why are they not reproducible? Because for the same reason, one set of mice don't correspond to another set of mice in another lab. So the point I'm making is 95% of your drugs are failing until now. After quarter of a trillion dollars in research, like you said,

that is between $6 billion a year right now I NCI funding and another six billion from philanthropic funding. Where is all this 12 billion dollars going? And then breast cancer are lo andries is six billion dollars in funding and what are they doing studying breast cancer Cell lines against drugs. Yes, it will get that young lady a PhD eventually and then she will try to get grants eventually she'll get fed up and go to industry and I must take exception with you condemning the industry. They are the easy target farmer companies. They are the easiest target but the system of research and development in America is that somebody like me, who is an academic researcher, will write a grant to NCI.

They will fund me for $250,000 a year for three to five years if I'm lucky. Well, let's put that in perspective, by the way. By NCI standards, that's a lot. And RO1 at this point, what is an RO1 down to now? Is it down to 450,000 a year for four to five years? Yeah. That's almost as big a grant as someone's going to get. Yes.

And with that, all you can do is study one gene, one signaling pathway, but let's say I luck out and I find something which I think is looking very encouraging and is a potential target. The next step is obviously to take it to the website, but to do that I have to now test this in mouse models first, in two mammals in fact, and then to take it to the website for a phase one trial alone will cost 30 million dollars. And by the time this drug will get approved, it will be $2.5 billion.

Nobody can fund that kind of work except industry. It's a very strange kind of thing where we are strange bed fellows, academics and industry. Academics will develop the biologic insights which are needed to identify targets, but we don't have the bandwidth to take it to the patient. So industry comes in, takes that. But then the bandwidth to take it to the patient. So, industry comes in, takes that, but then they have to bring it back to academics because that's where the universities

will help a few patients. So, do you, today, the criterion for recruiting young faculty, the young faculty is complaining to me, the Dr. Raza, all the universities where we are applying, ask us for is how many clinical trials are you going to open when you come? Yeah, look, it's a symptom of a broader issue, which is the incentives have come out of line. I don't know how to fix that, by the way, but even taking it once and further,

look just the entire system of publishing in academics has become So skewed because you took a good idea Which was wouldn't it be great if scientists would do work would publish them in journals would have them peer reviewed would share knowledge Broadly so that others might see it learn from it and not make the same mistakes and build on the work of others. A beautiful idea, you can't disagree with any of it. And by the way, recheck things that have been done to make sure they were done correctly because under different conditions, we want to make sure they're reproducible. Okay.

Understandably, then, that idea gets extended into this should be a criteria for promotion within the academic system, which invariably turns into an entire cottage industry of garbage journals and garbage study and garbage publications which are driving up the fraction of studies which can't be reproduced. And by the way, the fraction of studies that can't even get cited, they're so insignificant. And so you sort of think, my God, if something is pure and ideal as scientific research and publishing has become so difficult to do, and I don't have a great solution for that, the process you're describing is a logarithmic order in front of that, which is taking research from the so-called bench to the bedside.

That's the thing that I still don't, even after reading about this topic, and not just your book, but other books, I still don't have a great sense of what the future looks like. I don't disagree that the water is starting to get uncomfortably warm here as a little frog, and I don't disagree that we need to get out of this bath of water and into a cooler bath of water. But boy, I have to be honest with you, I'm discouraged. No, no, don't be. I have a solution for us and a very important solution. Peter Deraise is a writer who wrote a book in 1961, he wrote a novel because his own daughter who was 10 or 11 died of leukemia in his arms and after a horrible battle.

In 1961 Peter deraise says, so the treatment for leukemia today is a local rather than an express stream. Same run a few more stops. But that's how medicine functions, perfecting the art of prolonging disease. This was in 1961. How is this different? The run for leukemia is still a local. What I want to say is I feel like I'm living in a theater of the absurd. Why aren't other people seeing the spectacular failures we are dealing with and why do we keep moleculeing the public why do we keep Promoting the two three months or five months advantage in survival

Why aren't we going for bigger goals and better thing we can do it You know how we can do it is very simple what has worked in cancer until now? Early detection. How is it that we are living in an era of the most sophisticated technological advances possible? And yet the treatment of cancer is paleolithic. It belongs in the stone age, in the caves, giving the kind of disfiguring, horrible treatments we give is like beating someone said, this beating the dog with a baseball bat to get rid of its pleas. Have you ever seen somebody being treated with carti therapy? My God, there are whole industries frouting

up to control the side effects. Why are we even developing such terrible therapies? They yes, we should develop them, but they should be used when the tumor burden is not that high. So, once again, I want to be very clear about a couple of things before I give you my solution. Number one, I'm not against animal research at all. For biology, it is very important to use the animal model. All I'm against is drug development in animals

because what you learn in animals by using drugs is only correct for animals. It does not automatically extrapolate to human. So just to be clear, you're saying you would still use animals for safety, but you would disregard them for efficacy? I would not use them for safety either. Why should it give me any level of confidence that the drug didn't kill mouse, it wouldn't kill a human? It is very little to do with each other. We don't have to go into it now, but I guess do you know from sort of even back of the envelope

how that would change the regulatory landscape if we now had to go to a much earlier phase one in humans, obviously probably using a milder dose escalation, or would you be talking about doing primates instead? What is the actual model? None of those. In fact, the FDA has a system which is called phase zero in which you don't just bypass any animals. You use one 500 of the tools, starting tools in humans and work your way up that.

So basically it's homeopathic all the way up. Yeah, so that's how you do it with a phase zero trial. What I'm saying is, look, the only thing that has worked is early detection. We have great technology available. We shouldn't be talking about early detection doesn't work because mammograms have not been helpful, or PSA have left over diagnosis

and men undergoing very macabre surgeries and things. No. All I'm saying is that we should definitely take advantage of the cutting edge, genomics, transcriptomics, proteomics, metabolomics, the scanning and imaging devices that have been developed and use artificial intelligence to put all this together, develop 50 tests if we have to, to identify biomarkers which are based on all these things and combine them with the latest technology to try and start monitoring the human body not once a year, but continuously like a machine. And how do you do that? Well, you see this chip, you can see it. The audience cannot.

It's a small chip, the M chip. You can look it up because it is FDA approved. It is based on microfluidics. You put one drop of blood here, which goes through microfluidics and interacts with the biomarker put here. The biomarker in M chips case which is FDA approved is PSA. So men who have been diagnosed with a high PSA can use this chip it can slide into

a small device and very soon into your cell phone and give you your PSA four times a day if you want to see it. And if you're diagnosed with having a high PSA, you don't have to go in and have a complete abdominal resection with the removal of every lymph node and a BE vicarated. No, you follow this at home. If you have to as often as you want. I'm saying that if we develop a biomarker that is identifying the earliest footprints of a pancreatic cancer. We put that next in the next lane and for a variant cancer in the next door for each cancer we develop like a barcode and with one drop of blood. So, Poshiba a company just announced that they can detect 13 different cancers from one drop of blood in four hours, $180.

There's a company in the Bay Area that I follow very closely called Grail, and they're doing something very similar. At this point, they're, you know, in Phase 2 with probably almost 30 different cancers, I agree with you completely. I mean, my view of cancer is rule number one is don't get it. I mean, that sounds glib, but I don't think enough attention is paid to the don't get it rule, which is why aren't we trying to better understand what the environmental triggers of cancer are? Because well, as you point out, it has always been with us. I think there is

reasonable enough evidence to suggest that its incidence is higher in a modern world than in a non-modern world. And therefore, what is it about a modern world? For example, what is it about our diet or about our stress or our lack of exercise that could be amplifying our risk? And if you think about it, if changing factors of our lifestyle could reduce your risk of cancer by 30-50%, which my reading of the literature says is absolutely the case, how could we not make that a high priority to understand?

And when you pair the rule number one, don't get cancer with rule number two, very smart screening for cancer, you then get into rule number three, very smart screening for cancer. You then get into rule number three, which is if you get cancer, treat it so early, treat it when it is basically in the millions rather than the billions of cells. And for someone who might not have the familiarity with cells, a million cancer cells is not even detectable to the naked eye. A billion is. And so there's a very big difference between when you can catch a million cancer cells versus

a billion. And I agree with you, by the way, completely, that most people who are critics of early screening are unfortunately lacking the nuance to appreciate the accepted failures of things like PSA and mammography, which I won't go into here. I've covered them in great detail in some other podcasts. Two in particular, I'll just direct the listener to. I think the failures of PSA stand alone as a failure has been covered very well in the podcast with Ted Schaefer and Ted talks very eloquently about how if you are wed to PSA using PSA volume where you take PSA normalized to prostate volume and PSA velocity, which as rare you would

get out of what you propose, which is the rate of change of PSA over time. So PSA is a rate of change called PSA velocity, PSA volume become much better indicators of prostate cancer risk than just PSA, but also you go far beyond PSA to things like 4K and other types of test that add more nuance to this, I think the story becomes much more clear that this type of early detection matters. And I think as it pertains to the limitations of mammography, I would direct people to the podcast I did with Raj Atarawala, where we talked about cancer screening, and we actually very specifically address some of the limitations of the literature on these isolated techniques like mammography.

So you're not going to get any disagreement out of me on both of those fronts. So, I guess the question is, do we really believe that by taking those types of steps, we will reduce the need for the cancers for which we have just not had the big breakthroughs, which is basically lung, pancreas, prostate, breast, colon, and GBM. Those are basically the most lethal cancers. Outside of GBM, it's the metastatic versions of the others. Obviously, GBM doesn't leave the brain. It kills locally.

That's got to be two-thirds of cancer deaths. And you're basically saying, we have to catch these things long before they're ever in a position to leave the primary organ and not try to reinvent the onc drug discovery wheel coming up with another cocktail that's going to be as lucky as we were with Hodgkin's lymphoma. Is that, I don't want to put words in your mouth, but is that your view? Yeah. Well, sort of, but let me restate what specifically I feel. First of all, about the lifestyle you're talking about. Of course, lifestyle is, it's only common sense that if you smoke, it's not going to be good for you.

You'd like to get a lot of lung cancer, but many diseases will be high. you'd likely would have getting not just lung cancer, but many diseases will be high. So yes, lifestyle changes have, we have to continuously drill into our consciousness, what is good for us and what is bad for us and try not to get it. The problem is that with cancer, as I began by telling you,

heredity and pathogens and environmental exposure, like smoking, etc. Do account for a certain percentage, the vast majority, there is no reason why they get cancer. At least a reason that we can identify it yet. I think that's the challenge, is that with smoking, the difference between the people who smoked and the people who didn't smoked was so great

that it was appreciable, but you're right. With most other environmental contributors, with maybe the only other exception being obesity, it's very difficult to tease out what else could be contributing. For example, I don't know if your running or the trampoline is making enough of a difference because it's very difficult to study that longitudinally and prospectively and secondly I don't know that enough people are doing it and it would create a big enough signal that we can measure it. Well that's what I was going to say we don't even know whether eggs are good or bad for you to this day so those are the

kinds of issues with lifestyle large studies. Now the point I'm trying to make though is slightly different. A lot of people smoke, not all of them get cancer. So there are other co-factors that exist. All these things have to be worked out. Haven't we been trying for a hundred years? For God's sake, don't the investigators who act like this is something they have discovered today to be looked at. No, this is what we have been trying to do forever. It's not that simple. What we are finding is that for the vast majority of cancers, there are random mutations account for it, which means that cancer is most common with age, increasing age. Why? Because with age, many more of the cells in our body

have undergone several divisions. And with each division, we pick up some DNA copying errors due to three on an average. So by the time I sell is now from birth to like 60 years of age, every cell has undergone multiple cycles of proliferation. Therefore, multiple genes, generic mutations have collected, and these are making the cells susceptible that now it's like dropping grains of sand and they will form a pile and at one grain of sand which is no different than millions before that had gone before, it will suddenly cause an

avalanche and the pile will collapse, not because the glass grain of sand was different, but the pile had become unstable. So, with age, the body becomes unstable because all the cells have these kinds of mutations. So, and not only that metabolism can go wrong and sometimes as shown by whole genome sequencing of over 2000 tumors that there are a few cancers where no mutations were found in advanced cancers. So how did that happen? Well because sometimes it is the disturbed metabolism that then leads to a production of reduced oxygen species or free radicals, for example, that go and chop up and cause mutations and that generic mutations are a secondary event. The primary event is a metabolic disturbance. So, I mean, all this needs to be done, all this needs

to be studied and it isn't like it hasn't been studied. Since 1921, poor auto warberg made the first observation of anaerobic metabolism and since I was doing ketogenic type diets in the 1980s so please don't think that any of these things are new but the question that I am asking is someone who's been in this field for 43 years now is this if I'm still using 7 and 3 to 3 TML and for most common cancers, we are still using slash poison bird. It is not for lack of resources, it is not for lack of very, very smart people, hundreds of thousands of them who are working 16 hours a day to try and find the answer. But the answer is very complicated. It has too many aspects to it.

So the only thing we should do is I am besieging everybody in cancer related fields. Let's just spend a little more effort, a little more resources in earlier detection. Yes, keep trying to understand metabolic pathways and infrastrular signaling and checkpoints and parties and everything else. But instead of spending 5% in prevention, let's spend 50% in prevention and early detection, that is all I'm asking for. So a lot of people have asked me, Peter, because I've been completely uncompromising in my criticism, as you've heard now. I am completely merciless.

You know why? Because I have brought the patient back front and center and everything I look at is through patients, human anguish. Our problem is that 90% of our researchers never see a cancer patient because they are basic scientists and they study tumors that they grow on their own and their labs. So they don't see a disease, they are trying to develop treatment for and they are using animals who don't get these diseases spontaneously. How are people can you become for God's sake? So my thing is while you're doing all that at least let's employ all of this sophisticated

technology and a lot of the intellectual resources to developing biomarkers for early detection. Why not look at every compartment, whether it's blood, sweat, tears, saliva, urine, microbiome, study everything but human? Stop studying animals for God's sake, study human issue. You're making so much sense to me that I'm struggling to come up with a counter argument to that point you're making. I mean, should 50% of our resources be put into prevention and early detection rather than 4% if that? Absolutly. Should we also shift this two study disproportionately

in the study of interest, I couldn't agree with you more. You made a point a moment ago about the nature of contact. I wanted to use that as a point to come back to Omar. Why did you include the story of Omar in your book? He's not unique, right? I mean, you've treated a million Omar's. What was it about him that spoke to you so much? It had to be more than just his ethnicity, but I don't know. Maybe I shouldn't assume that. Well, first of all, he's my best friend, son. Here is a retired year old young man, a graduate of Oxford in Columbia. Teaching is finally fallen in love, calls his parents to come and get him engaged.

And when they arrive, the young couple, he has a little, Osteuagenic sarcoma. So the thing that has forced that made me put Umar into the book is the utter helplessness of oncologists, because from day one, when you have not resected that solid tumor completely, you were a surgeon, you were a surgical oncologist, you are a surgeon, you know this Peter, if you leave behind 10% of the tumor or even your microscopic pathology shows that cancer cells have entered blood vessels as was the case with Umar. Now you know that his chances of survival beyond a few couple of years at most are 0.00.

What are your choices you are going to give to Umar? Either you die of cancer or you die of the treatment we are going to give you. Because the problem is if we don't give treatment then death from cancer is horrendous in itself. It's one of the most painful deaths. So, are we at least doing some palliation? And Umar's case was really human. It's a good question you asked. It was emotionally soul-destroying to see this young man who's ready just embarking on his career. Finally, after years and years of hard work, as met the woman, he gets married a couple

of months after the diagnosis actually and knowing that he's going to die. And I had to live through every single day not just in the hospital but also at home because we are seeing him. And by the way if I recall this was only about five years after your husband died, yes? No longer. Harvey died in 2002. Umar died in 2009. Okay. Okay. Sorry. But yeah. Yes. Yeah, not that far. So I think also in the book, I tried to balance it out by presenting some elderly people like lady N. Kitty Seen, our older Harvey was older, whereas JC Andrew and Omar the three are younger people. So and different types of cancers I also wanted to show. So brain, tumor, osteogenics, sarcoma and a liquid tumor, then Harvey had a lymphoma. Many people ask me because

I have been so brutal in my criticism of everybody. And that's why I began telling you that, please, let's not just blame farmer companies. The hospitals who are supposed to be non-profit hospitals are making so many hundreds of millions of dollars in profits, what should they do? They have no shareholders to distribute it to. So they give large raises to their bureaucracy,

the executive business people running the hospital and then they start buying other hospitals and start investing in brick and mortar. This is what's happening. I, in fact, think about health care very much. I was talking to Perry Marshall the other day who was talking about higher education that in the post-COVID world one of the things that will be completely redone is higher education because the two variables who have skin in the game in higher education are students and teachers and students are embroiled in horrible loans by the time they graduate and teachers are not even hired in permanent positions anymore. There are adjunct professors that are hired, so you don't have to give them any kinds of benefits. And those two people have skin in the game suffer, whereas universities are developing endowments in billions of dollars. These are academic institutions, but I compare that same thing

to healthcare. The two people with skin in the game in healthcare are patients and doctors. Patients are fleeced for every last penny and doctors are overworked all the time. So we have no time to spend and businessmen are running the whole show. So I think the system has it's like that frog analogy over and over again. No one is going to give up what they're doing willingly at all. I believe exactly what Thomas Koon said. If you want to change the paradigm, you have to show a better one.

That's it. So how do we show a better paradigm? Well, at least I'm pointing to the only successful strategy in cancer is early detection. Why not use the latest technology to go for early detection? We can financially incentivize it and with the one success, the whole field can turn around because they will see that that's where it's a better thing to invest rather than in a venture

that has a 95% rate of failure. And mark my words, the coming decade of 2020 to 2030 will see this shift from treating the disease to trying to detect early and prevent the disease from becoming established. I agree with you. I really do agree with you. I don't know that I can speak convincingly to the time frame, but I am actually very optimistic with the potential of liquid biopsies and it's something we have been very eager. It's been a big part of our practice, frankly, inside of our practice and look forward to having a more rigorous discussion about this that's dedicated on the podcast when some of the technologies get through certain stages of FDA. That's right, I want to close with a question about the loss of your husband.

At any point during that ordeal, when he was struggling and you were right there with him and you had this young daughter, was there any point of you that was thinking, this is so unfair, the disease that you've devoted your life to, the disease that he has devoted your life to, the disease that he has devoted his life to, is ultimately the disease that's going to take him, and not just take him, but take him decades too soon. Or were you able to sort of come to this place of what some might call radical acceptance of just saying,

I accept what I can change, I have the courage to fight the things that I can and I have the courage to know the things that I can and I have the courage to know the distinction, you know, so-called serenity prayer. How did you go through that at such a young age? It's very hard to describe what one goes through. Of course I kick doors all the time and I had crying fits all the time and I remember calling my mother so often on weekends we used to talk,

she was in Karachi of course and I would say so many of my friends hate their husbands and they're doing fine and look at me I'm one who's crazy about Harvey and he's dying in front of my eyes. I went through every human emotion that why would go through especially because our daughter was so little. And Harvey is the one who actually had reached the point of acceptance. And when I would lose it every now and then in front of him, he would very calmly tell me not to worry about it.

It's just the luck of the draw as, don't worry. And he would one time, he said, look, when he was diagnosed, he was initially told his diagnosis. His reaction was so quintessential, Harvey. He said, well, I'm glad it's me and not you or Shahrzad. This I can handle that I couldn't. And so when you're going through something like caring for someone who you love, but who has made you responsible for every decision as well.

I'll also end by quoting my favorite Dickinson again, which is what one has to do. I had no time to hate because the grave would hinder me and life was not so ample, I could finish and matey nor had I time to love but since some industry must be this little toil of love I thought was large enough for me. That's a treat I don't get often. And the listeners I think will agree that it's not every day you tune into a podcast where you get treated to both

this sort of the literary sprinklings of greatness coupled with a, you know, a difficult, but a very important discussion about a disease that is going to touch anybody listening to this because if we're fortunate enough to not be the ones who get it, we are going to know somebody who does. It is tragically that ubiquitous a disease. I want to thank you for your time today, and I want to thank you for the work you've put into this. And finally, your patience. It has taken far too long to get this

interview on the books and I hope that the listeners will at least agree it was worth the wait. Well, before we end, Peter, I do want to say that since 1984 as a result of my experience with a patient. I started saving samples on them. So, blood and bone marrow biopsies and aspirates and two germline controls, T cells and buckles mirrors, seven different types of cells like CD34 separation, neutrophils separated, mononuclear cells separated, all kinds of elaborate things. And today, this tissue repository has over 60,000 samples from thousands of patients who have been seriously followed for years, some of them. And not a single cell comes from a second oncologist. To this day, I do all the bone marrow with my own hands. So this tissue repository which

contains samples of all sorts following the natural history of diseases in patients as they progress from a pre leukemia to acute leukemia is a national treasure. It's a repository which can really unravel so much and trace back to the cell of origin. Be for cell, find the biomarkers that are associated with a pre-Lukimia that spiraled out of control into a QQKMIA within months compared to one that took 15 years to become one. months compared to one that took 15 years to become one. I think that I want to end by saying in a very positive way that I am extremely optimistic about the future even though we spent most of our time in talking about very negative and very depressing pessimistic review of what the field has been. The future looks extremely bright and I am so happy that I have collected all this tissue which can now be used in the service to finally study the whole tissue repository properly and find that for itself. Thank you so much for the time you have given me today. I wish you the best as you remain in quarantine. I wish you a safe reentry in New York when the time comes.

Thank you. Thank you for listening to this week's episode of The Drive. If you're interested in diving deeper into any topics we discuss, we've created a membership program that allows us to bring you more in-depth, exclusive content without relying on paid ads. It's our goal to ensure members get back much more than the price of the subscription. Now, to that end, membership benefits include a bunch of things. One, totally kick ass comprehensive podcast show notes that detail every topic paper person thing we discuss on each episode. The word on the street is nobody's show notes rival these.

Monthly AMA episodes are asking me anything episodes hearing these episodes completely. Access to our private podcast feed that allows you to hear everything without having to listen to spills like this. The Qualies, which are a super short podcast, typically less than five minutes that we release every Tuesday through Friday, highlighting the best questions, topics, and tactics discussed on previous episodes of the drive. This is a great way to catch up on previous episodes without having to go back and necessarily listen to everyone. Steep discounts on products that I believe in, but for which I'm not getting paid to endorse.

And a whole bunch of other benefits that we continue to trickle in as time goes on. If you want to learn more and access these member-only benefits, you can head over to peteratiamd.com forward slash subscribe. You can find me on Twitter, Instagram, and Facebook all with the ID, Peter, Attia, MD. You can also leave us a review on Apple Podcasts or whatever podcast player you listen on. This podcast is for general informational purposes only. It does not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own

risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. Finally, I take conflicts of interest very seriously. For all of my disclosures in the companies I invest in or advise, please visit peteratia-md.com forward slash about where I keep an up to date and active list of such companies. Thank you.